ERBB2 and breast carcinoma: Although there is significant overlap, the national screening programs could increase their relevance to breast cancer by adding several new end points, including a) Her2 activation, b) progesterone receptor activity, c) prolactin effects, d) comprehensive coverage of ERβ activity, and e) expression of additional genes that are relevant to breast cancer.